Product Description
Mechanisms of Action: URAT1 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Gout|Kidney Failure, Chronic|Heart Failure, Diastolic|Heart Failure, Chronic|Type 2 Diabetes|Albuminuria|Kidney Diseases
Phase 1: Kidney Failure, Chronic|Gout|Healthy Volunteers|Kidney Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
AMETHYST | P2 |
Completed |
Heart Failure, Diastolic|Heart Failure, Chronic |
2022-04-29 |
|
AMETHYST | P2 |
Completed |
Heart Failure, Diastolic|Heart Failure, Chronic |
2022-04-29 |
|
SAPPHIRE | P2 |
Completed |
Kidney Failure, Chronic |
2021-11-22 |
|
SAPPHIRE | P2 |
Completed |
Kidney Diseases |
2021-11-22 |